{"protocolSection": {"identificationModule": {"nctId": "NCT00437645", "orgStudyIdInfo": {"id": "CVAA489A2404"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension", "officialTitle": "A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Alone"}, "statusModule": {"statusVerifiedDate": "2014-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-02-16", "studyFirstSubmitQcDate": "2007-02-20", "studyFirstPostDateStruct": {"date": "2007-02-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-17", "resultsFirstSubmitQcDate": "2011-01-17", "resultsFirstPostDateStruct": {"date": "2011-02-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-11-03", "lastUpdatePostDateStruct": {"date": "2014-11-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Study Director", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean sitting systolic blood pressure \\[msSBP\\] \u2265 130 mmHg and \u2264 160 mmHg) on amlodipine 5 mg alone. The study evaluated both the efficacy and tolerability of the treatments by providing data that assessed blood pressure and the proportion of patients developing peripheral edema."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Essential hypertension", "blood pressure", "edema", "valsartan", "amlodipine", "combination treatment"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1183, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/amlodipine 160/5 mg", "type": "EXPERIMENTAL", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.", "interventionNames": ["Drug: Valsartan 160 mg capsules", "Drug: Amlodipine 5 mg capsules", "Drug: placebo"]}, {"label": "Amlodipine 10 mg", "type": "ACTIVE_COMPARATOR", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.", "interventionNames": ["Drug: Valsartan 160 mg capsules", "Drug: Amlodipine 5 mg capsules", "Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "Valsartan 160 mg capsules", "armGroupLabels": ["Amlodipine 10 mg", "Valsartan/amlodipine 160/5 mg"]}, {"type": "DRUG", "name": "Amlodipine 5 mg capsules", "armGroupLabels": ["Amlodipine 10 mg", "Valsartan/amlodipine 160/5 mg"]}, {"type": "DRUG", "name": "placebo", "description": "capsules", "armGroupLabels": ["Amlodipine 10 mg", "Valsartan/amlodipine 160/5 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "timeFrame": "Baseline to Week 8"}, {"measure": "Percentage of Patients With Peripheral Edema From Baseline to Week 8", "description": "Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis.", "timeFrame": "Baseline to Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "timeFrame": "Baseline to Week 8"}, {"measure": "Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "timeFrame": "Baseline to Weeks 4, 8, and 12"}, {"measure": "Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12", "description": "Systolic response was defined as msSBP \\< 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.", "timeFrame": "Baseline to Weeks 4, 8, and 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients \u2265 55 years of age\n* Patients with essential hypertension measured using a validated automated oscillometric device at Visit 1\n* Non-treated patients must have a MSSBP \u2265 140 mmHg and \u2264 160 mmHg\n* Patients pre-treated on monotherapy prior to Visit 1 must have MSSBP \u2264 160 mmHg\n* To be eligible for randomization at Visit 2 (Day 1) all patients must have a MSSBP \u2265 130 mmHg and \u2264 160 mmHg\n* No peripheral edema at Visit 2 (randomization)\n* Written informed consent to participate in this study prior to any study procedures\n\nExclusion Criteria:\n\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant\n* Known or suspected contraindications, including history of allergy or hypersensitivity to angiotensin receptor blockers, calcium channel blockers, or to drugs with similar chemical structures\n* Patients taking more than 1 antihypertensive medication at Visit 1\n* Administration of any agent indicated for the treatment of hypertension after Visit 1 with the exception of pre-treated patients that require tapering down of anti-hypertensive treatments. For patients with previous antihypertensive medication that require a gradual downward titration, the tapering down should be done according to manufacturers instructions and last dose should be taken by week -2 prior to randomization\n* msSBP \\> 180 mmHg or msDBP \\> 110 mmHg at any time between Visit 1 and Visit 2\n* Evidence of a secondary form of hypertension, including but not limited to any of the following: Coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, polycystic kidney disease, or pheochromocytoma\n* History of hypertensive encephalopathy, cerebrovascular accident, transient ischemic attack, myocardial infarction, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) 12 months prior to Visit 1\n* History of heart failure Grade II - IV according to the NYHA classification\n* Second or third degree heart block with or without a pacemaker\n* Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia\n* Concomitant unstable angina pectoris\n* Clinically significant valvular heart disease\n* Patients with Type 1 diabetes mellitus\n* Patients with Type 2 diabetes mellitus who are not well controlled based on the investigator's judgment. It is recommended that Type 2 diabetic patients are adequately controlled and, if treated with medication, be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to Visit 1\n* Evidence of hepatic disease as determined by one of the following: AST or ALT values \\> 2x UNL at study entry, a history of hepatic encephalopathy, history of esophageal varices, or history of portocaval shunt\n* Evidence of renal impairment as determined by one of the following: serum creatinine \\> 1.5 x UNL at visit 1, history of dialysis, or history of nephrotic syndrome\n* Serum potassium values \\> 5.5 mmol/L at study entry\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug\n* Any surgical or medical condition which, at the discretion of the investigator or Novartis medical monitor, places the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study period\n* Volume depletion based on the investigator's clinical judgment using vital signs, skin turgor, moistness of mucous membranes, and laboratory values\n* Any severe, life-threatening disease within the past five years\n* History of drug or alcohol abuse within the last 2 years\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* Inability to communicate and comply with all study requirements including the unwillingness or inability to provide informed consent\n* Persons directly involved in the execution of this protocol", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "55 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "sites in Argentina", "city": "Agentina", "country": "Argentina"}, {"facility": "sites in Chile", "city": "Chile", "country": "Chile"}, {"facility": "sites in Ecuador", "city": "Ecuador", "country": "Ecuador"}, {"facility": "sites in Finland", "city": "Finland", "country": "Finland"}, {"facility": "sites in France", "city": "France", "country": "France"}, {"facility": "sites in Germany", "city": "Germany", "country": "Germany"}, {"facility": "sites in Italy", "city": "Italy", "country": "Italy"}, {"facility": "sites in Norway", "city": "Norway", "country": "Norway"}, {"facility": "sites in Spain", "city": "Spain", "country": "Spain"}, {"facility": "sites in Sweden", "city": "Sweden", "country": "Sweden"}, {"facility": "sites in Switzerland", "city": "Switzerland", "country": "Switzerland"}, {"facility": "sites in Turkey", "city": "Turkey", "country": "Turkey"}]}, "referencesModule": {"references": [{"pmid": "19196360", "type": "DERIVED", "citation": "Schrader J, Salvetti A, Calvo C, Akpinar E, Keeling L, Weisskopf M, Brunel P. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009 Feb;63(2):217-25. doi: 10.1111/j.1742-1241.2008.01977.x."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "FG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "592"}, {"groupId": "FG001", "numSubjects": "591"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "557"}, {"groupId": "FG001", "numSubjects": "476"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "115"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "84"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Condition no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "BG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "592"}, {"groupId": "BG001", "value": "591"}, {"groupId": "BG002", "value": "1183"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Age (years)", "classes": [{"title": "Overall study", "categories": [{"measurements": [{"groupId": "BG000", "value": "65.6", "spread": "7.56"}, {"groupId": "BG001", "value": "65.4", "spread": "7.16"}, {"groupId": "BG002", "value": "65.5", "spread": "7.36"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "285"}, {"groupId": "BG001", "value": "284"}, {"groupId": "BG002", "value": "569"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "307"}, {"groupId": "BG001", "value": "307"}, {"groupId": "BG002", "value": "614"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who had a baseline and at least one post-baseline efficacy assessment. For patients who discontinued prior to Week 8, the last post-baseline msSBP measurement collected was used for the analysis (last observation carried forward \\[LOCF\\]).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "567"}, {"groupId": "OG001", "value": "510"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.01", "spread": "0.5944"}, {"groupId": "OG001", "value": "-6.30", "spread": "0.6088"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Statistical analysis for non-inferiority of valsartan/amlodipine 160/5 mg to amlodipine 10 mg alone with a non-inferiority margin of 3 mm Hg", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.00", "ciUpperLimit": "-0.44", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.65"}]}, {"type": "PRIMARY", "title": "Percentage of Patients With Peripheral Edema From Baseline to Week 8", "description": "Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis.", "populationDescription": "Safety population: All randomized patients.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "592"}, {"groupId": "OG001", "value": "591"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.6"}, {"groupId": "OG001", "value": "31.1"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who had a baseline and at least one post-baseline efficacy assessment. For patients who discontinued prior to Week 8, the last post-baseline msSBP measurement collected was used for the analysis (last observation carried forward \\[LOCF\\]).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "567"}, {"groupId": "OG001", "value": "510"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.65", "spread": "0.3616"}, {"groupId": "OG001", "value": "-4.13", "spread": "0.3690"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who had a baseline and at least one post-baseline efficacy assessment. For patients who discontinued prior to Week 8, the last post-baseline msSBP measurement collected was used for the analysis (last observation carried forward \\[LOCF\\]).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Weeks 4, 8, and 12", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "576"}, {"groupId": "OG001", "value": "535"}]}], "classes": [{"title": "msSBP: Week 4 (n=576, 535)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.40", "spread": "0.5559"}, {"groupId": "OG001", "value": "-6.48", "spread": "0.5676"}]}]}, {"title": "msSBP: Week 8 (n=567, 510)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.15", "spread": "0.6065"}, {"groupId": "OG001", "value": "-6.11", "spread": "0.6266"}]}]}, {"title": "msSBP: Week 12 (n=569, 531)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.08", "spread": "0.6968"}, {"groupId": "OG001", "value": "-7.82", "spread": "0.7088"}]}]}, {"title": "msDBP: Week 4 (n=576, 535)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.05", "spread": "0.3559"}, {"groupId": "OG001", "value": "-4.23", "spread": "0.3623"}]}]}, {"title": "msDBP: Week 8 (n=576, 510)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.68", "spread": "0.3632"}, {"groupId": "OG001", "value": "-3.97", "spread": "0.3736"}]}]}, {"title": "msDBP: Week 12 (n=569, 531)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.50", "spread": "0.03735"}, {"groupId": "OG001", "value": "-4.90", "spread": "0.3785"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12", "description": "Systolic response was defined as msSBP \\< 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who had a baseline and at least one post-baseline efficacy assessment. For patients who discontinued prior to Week 8, the last post-baseline msSBP measurement collected was used for the analysis (last observation carried forward \\[LOCF\\]).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline to Weeks 4, 8, and 12", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "576"}, {"groupId": "OG001", "value": "535"}]}], "classes": [{"title": "Week 4 (n=576, 535)", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.07"}, {"groupId": "OG001", "value": "25.42"}]}]}, {"title": "Week 8 (n=567, 510)", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.22"}, {"groupId": "OG001", "value": "25.49"}]}]}, {"title": "Week 12 (n=569, 531)", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.96"}, {"groupId": "OG001", "value": "31.26"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.", "seriousNumAffected": 11, "seriousNumAtRisk": 592, "otherNumAffected": 61, "otherNumAtRisk": 592}, {"id": "EG001", "title": "Amlodipine 10 mg", "description": "Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.", "seriousNumAffected": 8, "seriousNumAtRisk": 591, "otherNumAffected": 201, "otherNumAtRisk": 591}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Gastrointestinal necrosis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Hantavirus pulmonary infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Drug toxicity", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Dysphasia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Neglect of personal appearance", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Bladder tamponade", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 591}]}, {"term": "Epididymitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 591}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 43, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 186, "numAtRisk": 591}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 592}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 591}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Disclosure Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M7657", "name": "Edema", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}